Annovis Bio Seeks to Double Authorized Shares to 140M Amid Cash Crunch
ANVS sits 16% above its 52-week low of $1.541.
Summary
Annovis Bio is seeking shareholder approval to double authorized common stock to 140 million shares and increase preferred stock to 10 million, providing headroom for future capital raises amid a tight cash position.
Key Events · Corporate Governance and Compliance · ANVS
-
Authorized Shares Doubling Proposed
Proposal 1 would increase authorized Common Stock from 70,000,000 to 140,000,000 shares and Preferred Stock from 2,000,000 to 10,000,000 shares.
-
Dilution Headroom Created
With 42,606,152 shares outstanding, the amendment would create approximately 97.4 million additional common shares available for issuance — more than doubling potential dilution if fully utilized.
-
Option Plan Ratification Sought
Proposal 2 seeks ratification of a prior equity plan amendment that contained a typographical error, understating the incremental share increase as 1,000,000 instead of the intended 2,500,000 shares.
-
Cash Runway Pressure
The company reported only $18.7 million in cash as of Q2 2026 and has a going concern warning, making future equity raises likely.
Analysis · ANVS · Life Sciences
Annovis Bio is asking shareholders to approve a doubling of authorized common stock from 70 million to 140 million shares, plus an increase in preferred stock from 2 million to 10 million. With only $18.7 million in cash as of Q2 2026 and a going concern warning already on file, the company needs flexibility to raise capital to fund its Phase 3 Alzheimer's trial. The proxy also seeks ratification of a previously approved equity plan amendment that contained a typographical error understating the share increase. If approved, the additional authorized shares create significant potential dilution for existing holders, though no shares are being issued immediately.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $1.79 on NYSE in the Life Sciences sector, with a market capitalization of approximately $74.6M. The 52-week trading range was $1.54 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.